Production at Rosplasma

Companies "NatsimBio" (a subsidiary of Rostec State Corporation), Kedrion Biopharma (Italy), and "Pharmstandard" have signed a memorandum on the joint implementation of projects in the field of blood plasma drug production.

Investments in completing the construction of "Rosplazma" in Kirov are estimated at 4 billion rubles.

The project involves the creation of a joint production facility in the Kirov Region. The plan includes a technology transfer from the Italian partner to launch the unfinished Kirov plant "Rosplazma," according to a statement released today by "NatsimBio."

It is planned that "Rosplazma" will produce albumin, immunoglobulin, and blood clotting factors VIII and IX. As stated by the CEO of Rostec, Sergey Chemezov, during the signing of the memorandum, "the Kirov site will eliminate our country's current dependence on the import of blood plasma drugs."

It is worth recalling that the plant is planned to be completed by 2019. This year, a decision was made at the government level to transfer the production site to Rostec. According to www.vademec.ru, investments in the project will amount to 4 billion rubles. To complete the plant's construction and launch its operations, "NatsimBio" plans to use funds from private investors.

Additionally, in October, the Acting Governor of the Kirov Region, Igor Vasiliev, announced the readiness of the regional authorities to support the project to ensure the construction is completed in the shortest possible time.